IL160896A0 - Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors - Google Patents

Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors

Info

Publication number
IL160896A0
IL160896A0 IL16089602A IL16089602A IL160896A0 IL 160896 A0 IL160896 A0 IL 160896A0 IL 16089602 A IL16089602 A IL 16089602A IL 16089602 A IL16089602 A IL 16089602A IL 160896 A0 IL160896 A0 IL 160896A0
Authority
IL
Israel
Prior art keywords
preparing
processes
muscarinic receptor
receptor inhibitors
quinuclidine derivatives
Prior art date
Application number
IL16089602A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of IL160896A0 publication Critical patent/IL160896A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
IL16089602A 2001-10-17 2002-09-23 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors IL160896A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01124727 2001-10-17
PCT/EP2002/010644 WO2003033495A1 (en) 2001-10-17 2002-09-23 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors

Publications (1)

Publication Number Publication Date
IL160896A0 true IL160896A0 (en) 2004-08-31

Family

ID=8178984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16089602A IL160896A0 (en) 2001-10-17 2002-09-23 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors

Country Status (19)

Country Link
US (1) US7361668B2 (xx)
EP (1) EP1438309A1 (xx)
JP (1) JP2005512974A (xx)
KR (1) KR20050030169A (xx)
CN (1) CN1571787A (xx)
BG (1) BG108683A (xx)
BR (1) BR0212983A (xx)
CA (1) CA2462980A1 (xx)
CZ (1) CZ2004501A3 (xx)
HU (1) HUP0401849A3 (xx)
IL (1) IL160896A0 (xx)
IS (1) IS7186A (xx)
MX (1) MXPA04002983A (xx)
NO (1) NO20042023L (xx)
NZ (1) NZ532283A (xx)
PL (1) PL370087A1 (xx)
RU (1) RU2004110717A (xx)
WO (1) WO2003033495A1 (xx)
ZA (1) ZA200402060B (xx)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438309A1 (en) * 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
AU2003222738B2 (en) 2002-05-07 2009-09-17 Neurosearch A/S Novel azacyclic ethynyl derivatives
WO2004004629A2 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
AR045913A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
TW200519109A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005037280A1 (en) * 2003-10-14 2005-04-28 Glaxo Group Limited Muscarinic acetycholine receptor antagonists
JP2007509061A (ja) * 2003-10-17 2007-04-12 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
WO2008076269A2 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
WO2008096094A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
JP2010525020A (ja) * 2007-04-24 2010-07-22 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ムスカリン性受容体への親和性を有する複素環式化合物
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2296471A4 (en) 2008-05-15 2012-03-14 Univ Toledo MUSCARIC ACID AGONISTS AS COGNITIVE ENHANCERS
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
WO2009152392A2 (en) * 2008-06-11 2009-12-17 University Of Toledo Muscarinic agonists for neurological disorders and methods of making the same
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
CN106518840B (zh) * 2016-11-17 2019-03-01 山东铂源药业有限公司 一种2-氯噻吩-5-甲酸的合成方法
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
GB9127279D0 (en) * 1991-12-23 1992-02-19 Ici Plc Heterocyclic derivatives
GB9216721D0 (en) 1992-08-06 1992-09-23 Ici Plc Therapeutic heterocyclic derivatives
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5384462A (en) 1992-12-08 1995-01-24 Levitt; Roy C. Process and apparatus for localizing a source of charged particles using an electric field
GB9226573D0 (en) * 1992-12-21 1993-02-17 Ici Plc Heterocyclic compounds
JPH08134067A (ja) * 1994-11-11 1996-05-28 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
EP0812840A4 (en) 1995-03-02 1999-02-10 Yamanouchi Pharma Co Ltd NOVEL QUINUCLIDINE DERIVATIVES WITH AN ANNELE TRICYCLIC HETERO CORE
JP4206212B2 (ja) * 1999-09-28 2009-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 キヌクリジン化合物およびそれを有効成分として含有する医薬
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
EP1438309A1 (en) * 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors

Also Published As

Publication number Publication date
RU2004110717A (ru) 2005-10-20
NO20042023L (no) 2004-05-14
HUP0401849A3 (en) 2007-05-02
MXPA04002983A (es) 2004-07-15
HUP0401849A2 (hu) 2004-12-28
PL370087A1 (en) 2005-05-16
BG108683A (en) 2005-04-30
CZ2004501A3 (cs) 2004-09-15
IS7186A (is) 2004-03-18
EP1438309A1 (en) 2004-07-21
BR0212983A (pt) 2004-10-13
ZA200402060B (en) 2005-03-15
CN1571787A (zh) 2005-01-26
NZ532283A (en) 2005-06-24
KR20050030169A (ko) 2005-03-29
WO2003033495A1 (en) 2003-04-24
US7361668B2 (en) 2008-04-22
CA2462980A1 (en) 2003-04-24
US20050020660A1 (en) 2005-01-27
JP2005512974A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
HUP0401849A3 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
TWI349672B (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
HK1089768A1 (en) Indolone-acetamide derivatives, processes for preparing them and their uses
HK1070358A1 (en) Process for the preparation of 7-substituted-3-qu inoline and 3-quinol-4-one carbonitriles.
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
HK1069578A1 (en) Method for preparing benzenesulfonyl compounds
IL174029A0 (en) Process for preparing 2-oxo-1-pyrrolidine derivatives
ZA200702523B (en) Process for the purification of 1,4-butanediol
TWI346574B (en) A catalyst composition, a process for preparing the catalyst composition and a use of the catalyst composition
EP1467758A4 (en) PREPARATION OF IMMUNOCONJUGATES
HK1068336A1 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
EP1551833A4 (en) PROCESS FOR THE PREPARATION OF (S, S) -CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE
IL161120A0 (en) Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
IL164248A0 (en) Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
EP1507781A4 (en) METHOD OF PREPARING MAYTANSINOL
HK1100946A1 (en) 1-a-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
EP1781678A4 (en) 1 -? - HALOGEN-2,2-DIFLUOR-2-DESOXY-D-RIBOFURANOSEDERIVATE AND PROCESS FOR THE PRODUCTION THEREOF
IL164407A0 (en) Processes for preparing heteroaryl and unsaturatedheterocycloalkylmagnesium compounds
IL159561A0 (en) Eurotinones and derivatives thereof, processes for preparing them, and their use
AU2003264894A8 (en) Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses
IL160606A0 (en) C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
EP1515960A4 (en) 2-THIOXOTHIAZOL DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
EP1451178A4 (en) PROCESS FOR PREPARING BEAT D RIBOFURANOSE DERIVATIVES
IL160938A (en) Coniosulphides and their derivatives, processes for preparing them and their use as pharmaceuticals